We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Details of certificates issued under the Special Import System for the top ten veterinary medicines that were imported 1 July - 30 September 2023.
For manufacturers and distributors of intermediate and final feedingstuffs containing a medicinal premix or specified feed additives.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
Guidance for specialists for initiation of valproate in female patients and for annual review and pregnancy testing to support adherence to pregnancy prevention requirements during the pandemic.
Information for healthcare professionals and the public about the Pfizer/BioNTech's bivalent vaccines
Guidance for the pharmaceutical industry on Marketing Authorisations for veterinary medicines in the UK.
Falsified, potentially harmful Ozempic▼ and Saxenda products have been found in the UK.
Systematic reviews and meta-analyses of randomised controlled trials have highlighted a dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors treated with omega-3-acid ethyl ester medicines compared to placebo.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (27 December) approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of 12.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
Information for those who have been prescribed Paxlovid.
A form of IP that extends the protection of patented active ingredients present in pharmaceutical or plant protection products.
We are providing an update on a retrospective observational study on the risk to children born to men who took valproate in the 3 months before conception and on the need for the re-analysis of the data from this study...
How to account for VAT on goods and services provided by registered health professionals, including doctors, dentists, nurses and pharmacists.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
Product Safety Report for Esapharma Movate Steroid Cream presenting a serious chemical risk.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).